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ABSTRACT The soluble cleaved urokinase plasmin-
ogen activator receptor (scuPAR) is a circulating pro-
tein detected in multiple diseases, including various
cancers, cardiovascular disease, and kidney disease,
where elevated levels of scuPAR have been associated
with worsening prognosis and increased disease aggres-
siveness. We aimed to identify novel genetic and bio-
molecular mechanisms regulating scuPAR levels. Ele-
vated serum scuPAR levels were identified in asthma
(n514) and chronic obstructive pulmonary disease
(COPD; n219) cohorts when compared to controls
(n96). In these cohorts, a genome-wide association
study of serum scuPAR levels identified a human
plasma kallikrein gene (KLKB1) promoter polymor-
phism (rs4253238) associated with serum scuPAR levels
in a control/asthma population (P1.17107), which
was also observed in a COPD population (combined
P5.041012). Using a fluorescent assay, we demon-
strated that serum KLKB1 enzymatic activity was driven
by rs4253238 and is inverse to scuPAR levels. Biochem-
ical analysis identified that KLKB1 cleaves scuPAR and
negates scuPAR’s effects on primary human bronchial
epithelial cells (HBECs) in vitro. Chymotrypsin was
used as a proproteolytic control, while basal HBECs
were used as a control to define scuPAR-driven effects.
In summary, we reveal a novel post-translational regu-
latory mechanism for scuPAR using a hypothesis-free
approach with implications for multiple human diseases.—
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The urokinase plasminogen activator receptor (uPAR;
also known as PLAUR and CD87) is a cellular receptor
for urokinase (uPA), which activates the plasminogen/
plasmin activation cycle and its extracellular proteolytic
cascade (1). uPAR also acts through nonproteolytic
functions, where associations with a number of cell-
bound factors, such as integrins and G-protein-coupled
receptors, allow uPAR to stimulate signaling cascades,
regulating functions such as cytoskeletal dynamics, cel-
lular adhesion, and cellular migration (2). Through its
proteolytic and nonproteolytic cascades, uPAR is in-
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volved in extracellular matrix remodeling, cell migra-
tion, coagulation, cellular proliferation, release of in-
flammatory cytokines, and growth factor activation (1).
uPAR exists as a glycosylphosphatidylinositol (GPI)-
anchored membrane protein [commonly defined as
membrane uPAR (muPAR); refs. 3–5] translated from
a 1.4-kb mRNA (4) from the PLAUR gene on the 19q13
chromosome (5). The PLAUR gene consists of 7 exons
(6), exon 1 containing the 5= untranslated region
(5=UTR) and a signal peptide, while exons 2–3, 4–5,
and 6–7 encode globular domains DI, DII, and DIII,
respectively (as numbered from the N terminus; ref. 6),
where DI and DII are known to be involved in uPA
binding and chemotaxis, and DIII is important for
integrin binding (e.g., 51; ref. 6).
This membrane-bound receptor is ubiquitously ex-
pressed on multiple cell types and tissues (6) and is
implicated in a number of diseases, including asthma (7,
8), cancer (9, 10), epilepsy (11), and cardiovascular
disease (12), suggesting an important biological role for
this protein. This is further supported at the cellular level,
where uPAR has been reported to be involved in efficient
epithelial wound repair (8), neutrophil recruitment dur-
ing cellular inflammation, tumor invasiveness, and metas-
tasis (13, 14), especially in breast cancer (15).
Apart from the membrane-bound form of the receptor,
a soluble cleaved form of uPAR (scuPAR) is also known to
exist. This arises from glycolytic and lipolytic cleavage of
muPAR’s GPI anchor, via a number of molecules, such as
GPI-specific phospholipase-D and cathepsin G (16). The
resulting scuPAR is known to exist under normal physio-
logical conditions in several biological fluids, including
serum (17) and induced sputum (18). Furthermore,
scuPAR has a role in trafficking of neutrophils to sites of
inflammation (2) and local mobilization of stem cells
(19). While total scuPAR levels are stable in healthy
individuals (4), high circulating levels of the soluble
receptor have been described in a number of diseases,
including ventilator associated pneumonia (20), HIV
(21), cardiovascular disease, and cancer (22). In these
disease states, scuPAR is frequently reported to act as a
biomarker, with high scuPAR levels linked to patient
mortality rates and increased disease aggressiveness (22,
23). This has previously led to the suggestion that scuPAR
may be of value as a prognostic marker of disease.
However, recent investigations have identified a direct
role for elevated levels of freely circulating scuPAR in the
serum of subjects with focal segmental glomerulosclerosis
(FSGS; ref. 24). Here, scuPAR did not only act as a marker
of disease, but also played an active role in the develop-
ment and modulation of the disease through interaction
with 3 integrins on the kidney’s visceral epithelial cells
(podocytes; ref. 24). This functional role for scuPAR is
independent of muPAR function and beyond that of a
uPA decoy receptor (8). This therefore indicates that
changes in freely circulating scuPAR may be important to
the development and modulation of multiple human
diseases. Therefore, furthering our understanding of the
mechanism regulating serum scuPAR levels would be of
importance in understanding the biology underlying the
receptor’s role in multiple disease states.
A number of studies have suggested that uPAR may
play a role in obstructive lung disease. We have previ-
ously identified PLAUR as an asthma susceptibility gene
(7). Here single-nucleotide polymorphisms (SNPs)
spanning the gene and its untranslated regions were
found to be associated with asthma susceptibility, bron-
chial hyperresponsiveness, lung function decline, and,
importantly, with increased serum scuPAR levels (7).
Similarly, in further independent studies, we have
shown that PLAUR SNPs are associated with baseline
lung function in smokers (25) and that uPAR is ele-
vated in the airway epithelium in asthma (8).
This study aimed to determine whether scuPAR is
elevated in patients with obstructive lung disease and to
identify a novel regulatory mechanism for scuPAR,
through a genome-wide association study (GWAS),
which may be of relevance to scuPAR associated dis-
ease. Here we demonstrate that serum scuPAR is signif-
icantly elevated in asthma and COPD patient serum.
Following this we successfully employed a GWAS, iden-
tifying a novel genetic mechanism determining uPAR
levels and successfully demonstrated that the biochem-
ical and functional basis of the described association is
driven by a human plasma kallikrein gene (KLKB1)
cleavage of uPAR. Finally we utilized in vitro epithelial
cell models to identify that the effects of scuPAR on
primary human cell function are negated in the pres-
ence of KLKB1, further confirming the important
modulating role of KLKB1 on uPAR function.
MATERIALS AND METHODS
Cohort characteristics
Asthma (n514) and control (n104) subjects were selected
from 200 families and 407 trios, both ascertained through an
asthmatic proband and characterized using a standardized
study protocol, with asthma from the northern part of the
Netherlands and studies with an identical protocol, as de-
scribed previously (26). Selection was based on whether
subjects had serum available for this study. Ethical approval
was obtained from the University of Groningen Medical
Ethics Committee (MEC 96/04/077 and MEC 90/09/178).
COPD (n219) subjects were recruited from UK centers
based on physician- and spirometry-defined COPD (FEV1/
FVC70%; FEV180%), Caucasian,40 yr old, smokers with
10 pack-yr history. Subjects with a previous diagnosis of
asthma were excluded (25). Ethical approval was obtained
from the Multicenter Research Ethics Committee (MREC/
99/4/001), and informed consent from all subjects was
obtained.
Analysis of soluble protein levels
Levels of scuPAR in human serum were determined using a
Duoset ELISA (R&D Systems, Abingdon, UK). Samples were
diluted 1:8 in 1% BSA in PBS. Levels of active supernatant
plasmin were determined in undiluted serum using the
SensoLyte AFC plasmin activity assay kit (Cambridge Biosci-
ence, Cambridge, UK). Assays were read at 450 nm (back-
ground subtraction 570 nm), using a Flexstation 3 microplate
reader (Molecular Devices, Wokingham, UK).
GWAS
A GWAS involving a data set of 295,196 SNPs genotyped on
the Illumina 300 and 370 chips (Illumina, Inc., San Diego,
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CA, USA) was carried out in 104 control subjects and 480
subjects with doctor-diagnosed asthma and hyperresponsive-
ness (histamine PC2032 mg/ml) with log10 serum scuPAR
levels as the outcome. Quality control included a SNP call rate
of 0.95, and the SNPs were in Hardy Weinberg equilibrium
(P1107). Related subjects were excluded using a PI HAT
cutoff of 0.1875, and ethnic outliers and cryptically related
subjects were removed with smartpca 8000 software (27).
Associations were investigated using linear regression in
PLINK 1.07 (additive model; ref. 28) with adjustment taken
into consideration for 2 eigenvectors in cases. Closer analyses
of regions determined to be of interest were carried out using
LocusZoom 1.1 (29). A value of P  1.69  107 was
considered significant using a Bonferroni correction. Infla-
tion factors  were calculated using WGAViewer 1.26 software
(30), and QQ and Manhattan plots were generated using R
2.15.0 (31). Meta-analysis was a fixed effect analysis carried
out in PLINK (28).
mRNA by SNP browser
Associations between changes in KLKB1 mRNA levels and
PLAUR expression were investigated using the mRNA by SNP
browser (32). This software incorporates a generic eQTL
database and provides a graphic interface for browsing asso-
ciation between 54,675 mRNA transcript levels and 406,912
SNPs. For each transcript, the browser provides association
test statistics (P0.001), estimates of effect size and allele
information across the genome. Data were obtained from
Epstein-Barr virus-transformed lymphoblastoid cell lines
taken from 206 families of British descent selected through a
proband of childhood asthma, with cells taken from affected
subjects and their sibling pairs regardless of whether the
sibling pair had asthma (n397 sibling pairs; 11 half sibling
pairs; ref. 32).
Prediction of changes in transcription factor binding sites
The region containing the SNP rs4253238 ranging from the
KLKB1 gene transcriptional start site up to 100 bp upstream
of the SNP was run through 3 transcription factor prediction
databases: MatInspector TF Mining tool (Genomatix Software
GmbH, Munich, Germany; http://www.genomatix.de); Tran-
scription Element Search System (TESS; Computational Biol-
ogy and Informatics Laboratory, University of Pennsylvania,
Philadelphia, PA; http://www.cbil.upenn.edu/cgi-bin/tess/
tess); and PROMO (http://alggen.lsi.upc.es/cgi-bin/promo_
v3/promo/promoinit.cgi?dirDBTF_8.3). Changes predicted by
all 3 packages were then considered.
HaploReg analysis
The regulatory potential of SNPs in LD to rs4253238 was
determined using HaploReg 2 (http://www.broadinstitute.
org/mammals/haploreg/haploreg.php). HaploReg makes
use of an expanded library of SNPs (based on dbSNP 137),
motif instances [based on pulse-width modulations discov-
ered from the Encyclopedia of DNA Elements (ENCODE)
experiments], enhancer annotations (adding 90 cell types
from the Roadmap Epigenome Mapping Consortium), and
eQTLs (from the GTex eQTL browser; ref. 33).
Haplotype analyses
Linkage disequilibrium analysis was carried out using Haplo-
view 4.2 (HapMap merged versions 1, 2, and 3, release 27 on
CEU population; region 4:18737100–18741700; KLKB1 gene
build ENSG00000164344; ref. 34).
KLKB1 activity assay
Serum samples (5 	l) were added in duplicate to 50 	l of the
H-Pro-Phe-Arg-AMC (Bachem, Bubendorf, Liestal, Switzer-
land) substrate in activity buffer. After a 5-min 25°C incuba-
tion, fluorescence was recorded (excitation 380 nm; emission
460 nm) using a Flexstation 3 microplate reader over 5 min.
This assay was validated by the addition of 2.5 	g of human
plasma extracted KLKB1 (Calbiochem-Merck, Nottingham,
UK) to 50 	l of the substrate in activity buffer.
Cell culture and collection of protein lysate
Normal human bronchial epithelial cells (NHBECs; Lonza, Wok-
ingham, UK) passage 3, from 2 male donors (8), were cultured in
fresh growth factor-supplemented medium (BEGM; Lonza), ex-
cluding gentamicin and amphotericin-B, in 6-well plates as de-
scribed previously (8). BEGM was changed to basal medium 24 h
prior to stimulation with KLKB1 (Calbiochem-Merck). Cells were
incubated for 4 and 24 h. Protein lysates were collected by the
addition of 100 	l of X1 SDS loading dye directly to cells, followed
by manual scraping and lysate recovery. Experiments were repeated
3 times/donor.
Quantitative PCR
Levels of total uPAR mRNA in primary HBECs treated with
and without KLKB1 (Calbiochem-Merck) were determined
using qPCR via the TaqMan method as described previously
(35). RNA was collected and isolated from cells using the
Qiagen RNeasy kit (Qiagen, Manchester, UK) and cDNA
synthesized using the SuperScript II Reverse Transcriptase kit
using random hexamers (Invitrogen, Paisley, UK).
Western blotting
Cell lysates were separated by 10% SDS-PAGE under reducing
conditions. Proteins were transferred to a PVDF membrane
and probed using the anti-uPAR DI antibody IIIF10 (Santa
Cruz Biotechnology, Heidelberg, Germany) and the anti-
uPAR polyclonal antibody BAF807 (R&D Systems). Detection
was via enhanced chemiluminescence (Amersham Biosci-
ences, Little Chalfont, UK). Membranes were stripped using
Restore Western blot stripping buffer (Thermo Fisher Scien-
tific, Cramlington, UK) and reprobed for loading controls
(-actin; ref. 8). Protein densitometry used ImageJ 1.41 (U.S.
National Institutes of Health, Bethesda, MD, USA; http://
rsbweb.nih.gov/ij/). For statistical analysis, data were normal-
ized to -actin and exposure levels.
KLKB1-mediated scuPAR digest
We next treated 200 ng of recombinant human uPAR (R&D
Systems) with 250 ng of KLKB1 at 37°C for 24 h. A protease
control (protease inhibitor cocktail mix; Roche, Welwyn
Garden City, UK), and a cleavage control (substitution of
KLKB1 with 108 ng of the known uPAR protease chymotryp-
sin; Roche) were used.
Preparation and transfection of plasmids
The pcDNA3
muPAR plasmid has been described previously
(8). The open reading frame of membrane uPAR (NM_
002659.3) minus the sequence coding for the GPI anchor was
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amplified using primers including a consensus Kozak sequence
and restriction enzyme sites (5= primer: 5=-ACTTGAATTCGC-
CACCATGGGTCACCCGCCGCT-3=; 3= primer: 5=-ACTTCTCG-
AGTTAACAGCCACTTTTAGTACAGC-3=). The PCR product
was cloned into pCR4-TOPO (Invitrogen) and then sub-
cloned into pcDNA3 (Promega, Southampton, UK) using
appropriate restriction enzymes and T4 ligase (Promega).
The scuPAR plasmid was sequence verified before transfection.
Wound-healing assay
NHBECs were cultured as above in 6-well plates. Cells were
transfected with muPAR- or scuPAR-overexpressing plasmids
(8) at 50% confluence using Fugene6 at a ratio of Fugene to
DNA of 3:2. Wound healing was carried out as described
previously (8). Percentage area healed was calculated using
CellProfiler (36).
Proliferation assay
NHBECs were cultured in 96-well plates and transfected as
above. At 20 h post-transfection, cells were exposed to a 0.5
mg/ml dimethyl-thiazolyl-diphenyl-tetrazolium solution (Sigma-
Aldrich, Dorset, UK) at 37°C for 4 h. Crystals were dissolved
in isopropanol and absorbance measured at 570 nm (back-
ground subtraction at 690 nm) using a Flexstation 3 micro-
plate reader.
Statistical analyses
Statistical analyses were carried out using SPSS (PASW) 16.0
(SPSS Inc., Chicago, IL, USA) or GraphPad Prism 5.03
(GraphPad, San Diego, CA, USA). Potential continual and
binary variable confounders for serum scuPAR level analyses
were systematically investigated in the regression model.
Variables included in the final model had a statistically
significant effect on scuPAR levels, i.e., age (in years at time of
sampling), height (in meters at time of sampling), weight (in
kilograms at time of sampling), and smoking (pack-year
value). Gender and geographical locations were not identi-
fied as confounders. Investigations into the association of
serum scuPAR levels with disease phenotypes were carried out
using Mann-Whitney and Kruskal-Wallis tests, followed by
secondary confirmatory analyses using linear regression, with
the inclusion of identified confounders. Duplication of
GWAS analysis in the COPD cohort was carried out in PLINK
(additive model) on the log10 transformed uPAR values. Data
from grouped analyses were analyzed using either a paired
1-way ANOVA or a 2-tailed paired t test carried out in PRISM.
RESULTS
Serum scuPAR levels are elevated in asthma and
COPD
Median serum scuPAR levels in 514 patients with asthma
(3306 pg/ml) and 219 patients with COPD (5844 pg/ml)
were elevated vs. 96 control subjects (2538 pg/ml)
(P0.001 and P1104, respectively; Fig. 1). Subjects
were selected based on the presence of full clinical
characteristics (see Table 1). There was a significantly
elevated level of scuPAR in COPD vs. those subjects with
asthma (P0.0001; Fig. 1). All analyses were corrected for
the identified confounders of age, height, weight, and
smoking (pack-years).
Genome-wide association identifies rs4253238 as a
determinant of scuPAR serum levels
We investigated 295,196 SNPs for association with scu-
PAR levels in serum. Quantile-quantile plots for con-
trols (n104) and patients with asthma (n480) iden-
tified a lack of deviation of observed P values from the
expected P values (Fig. 2A, B; inflation factor 0.996
and 1.003, respectively). In individual data sets, no SNP
achieved genome-wide significance, as defined by the
Bonferroni method (P1.69107). Analysis carried
out on the control and asthma result data sets (n584,
1.009) identified a region at 4q35 containing ge-
nome-wide significant associations for SNPs rs4253238
and rs1912826 [Fig. 2C, D; P(fixed effect)1.13
107]. These SNPs are in near complete linkage dis-
equilibrium (LD; D=0.99; R20.94) in the GWAS
population and so were considered as a single region of
variation, represented by rs4253238 for the remainder
of this study. The 4q35 region corresponds to the
promoter/5= coding region of the gene for human
plasma kallikrein (KLKB1; previously known as KLK3).
rs4253238 is associated with scuPAR levels
in a COPD population
SNP rs4253238 was genotyped in a COPD cohort
(n219) and was associated with serum scuPAR levels
(P5.34107; B0.16812 for log10-transformed uPAR lev-
els and additive allele coding). The association identi-
fied the same direction of effect on scuPAR levels as in
the asthma/control meta-analysis [median level for
genotypes C:C (6654 pg/ml)  T:C (5435 pg/ml) 
Figure 1. Elevated scuPAR in serum from patients with
asthma or COPD. Median levels are elevated in asthma (3306
pg/ml) and COPD (5836 pg/ml) when compared to controls
(2538 pg/ml). Patients with COPD also had a higher level of
scuPAR than patients with asthma. Lines denote median
scuPAR levels. *P  1  103, ***P  1  105.
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T:T (4412 pg/ml) (Fig. 2F–H), minor allele: C; Cauca-
sian (HapMap CEU) minor allele frequency (MAF)0.496
(Fig. 2H)].
A meta-analysis including the control, asthma, and
COPD populations (n803) further confirmed associa-
tion between rs4253238 and serum scuPAR (P5.037
1012; B0.0879). A significant degree of heterogeneity
of the effect between the studies (P0.02) was observed
and reflected a more pronounced effect by rs4253238
on serum scuPAR in COPD (B0.16812) than in patients
with asthma (B0.06972) or controls (B0.09129).
rs4253238 is in linkage disequilibrium with multiple
potentially functional KLKB1 SNPs
SNP rs4253238 is in LD with SNPs present in the KLKB1
5=UTR and coding regions in the HapMap Project (34)
Caucasian populations (Utah residents with ancestry
from northern and western Europe (n180), but not
with SNPs in other genes (Fig. 3B). The HaploReg
online tool (33) identified 31 SNPs in LD with
rs4253238 that have potential regulatory function on
KLKB1 gene expression using the 1000 genomes’ phase
1 data (see Supplemental Fig. S1).
A near genome-wide significant hit exists on the FXII
gene but is not observed in a COPD cohort
A second SNP located on chromosome 5 (rs2731672;
MAF0.190; HapMap CEU population), located in the
3= region of the factor XII gene, just failed to achieve
genome-wide significance (P7.83107; B0.0782
for log10 transformed uPAR level and additive allele
coding). However, no association was found between
the SNP and serum scuPAR in the COPD cohort
(P0.05). This may be explained by the fact that the
additive effect of this SNP is 2 times larger in the
controls (B0.1414) than in the patients with asthma
(B0.06204), identifying a possible effect unique to
nondiseased individuals. However, as we did not ob-
serve this association in an independent cohort
(COPD: B0.00016 and P0.997), we therefore fo-
cused on the locus defined by SNP rs4253238.
An in silico eQTL analysis does not identify
SNP rs4253238 as being associated with
uPAR mRNA
Comparisons between data generated from the protein
GWAS and in silico data from the mRNA by SNP
browser 1.0.1 (32) identified that rs4253238 did not
alter uPAR mRNA levels in this lymphoblastoid data-
base. The polymorphism located at rs4253238 was also
not found to regulate uPAR levels in a mRNA-based
investigation to determine genetic variants that affect
gene expression in human lung tissue (37). These data
suggested that the genetic association for rs4253238 did
not involve changes in mRNA and may be a post-
translational mechanism.
rs4253238 does not alter uPAR mRNA in a primary
epithelial cell population
Expanding on the in silico analysis, comparisons of mem-
brane uPAR mRNA levels in primary human bronchial
epithelial cells treated with and without KLKB1 con-
firmed that KLKB1 did not modulate membrane uPAR
expression at the mRNA level (Fig. 4).
rs4253238 genotype is associated with human plasma
kallikrein activity in serum
Using a validated activity assay, the KLKB1 rs4253238
genotype was associated with KLKB1 activity using a
fluorescent substrate in 10 randomly chosen homozy-
gote subjects (TT vs. CC) from each of the control,
asthma, and COPD populations (Fig. 5A). Presence of
the major (T) allele was associated with increased
KLKB1 activity in the control (P0.01), asthma
(P0.01), and COPD populations (P0.001). Notably,
KLKB1 activity was decreased in diseased patients when
compared to controls (P0.001). Serum KLKB1 activity
TABLE 1. Population demographics for patient serum samples
Parameter Control Asthma COPD
Maximum number 104 514 219
Percentage male 37.5% 44.9% 62.7%
Mean age (yr)* 50  8 40  12 68  8
Mean height (m) 1.71  0.08 1.74  0.09 1.67  0.88
Mean weight (kg) 76.35  12.1 78.12  15.7 70.23  18.1
Mean smoking (pack-yr)* 10.50  11.69 4.95  9.58 46.87  26.72
FEV1 pre- (%Pred)* 100.94  10.99 80.71  20.70 41.87  18.52
FEV1 post- (%Pred)* 104.78  11.32 92.42  18.73 47.53  19.39
FEV1/VC pre-* 0.80  0.05 0.70  0.14 0.45  0.13
FEV1/VC post-* 0.82  0.04 0.76  0.12 0.45  0.12
Reversibility (% change in FEV1
from baseline to salbutamol)* 3.91  4.43 11.72  7.10 6.64  3.29
BHR (PC20; mg/ml) 32 32 n/a
Subjects were selected from the total pool based on presence of complete clinical data for
phenotype analyses or genotype-specific quality control that excluded subjects. Pre- indicates measure-
ments taken prior to the administration of a bronchodilator (salbutamol). Post- indicates measurements
taken after the administration of a bronchodilator (salbutamol). BHR, bronchial hyperresponsiveness.
Values are means  sd. *P  0.01 across groups.
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was inversely correlated to serum scuPAR levels (P1
104; R20.278; Fig. 5B).
KLKB1 exposure reduces scuPAR protein levels in
bronchial epithelial cells and increases plasmin activity
We next determined the biological activity of KLKB1
on primary HBECs, which are key effector cells for
remodeling in asthma and COPD (38). HBECs from 2
Caucasian donors were cultured in the presence and
absence of KLKB1; scuPAR levels in supernatants of
HBECs treated with KLKB1 were decreased at 4 and 24
h (P0.015; P0.029; Fig. 5C). HBEC total intracellu-
lar uPAR protein levels (muPAR and suPAR) were
decreased following KLKB1 exposure at 24 h (P0.05;
Fig. 5D).
To investigate whether KLKB1 affects scuPAR
through modulation of the plasminogen activation
system we carried out a plasmin activity assay, identify-
ing a 3-fold increase in HBEC supernatant plasmin
activity at 4 h (P0.005), but not at 24 h after KLKB1
addition (Fig. 5E).
Figure 2. Serum scuPAR is associated with the KLKB1 SNP rs4253238. A, B) QQ plot for genome-wide analyses in control
(n104; A) and asthma (n480; B) populations. The QQ plots identify a modest deviation in the disease (asthma) population.
C) In an analysis of the asthma and control populations (n584), the QQ plot reveals that measured SNP log P values deviate
significantly from the expected trend denoted by the red trend line. D) Manhattan plot identifies a single region as the
genome-wide significant in a combined asthma/control population analysis (P1.69107). This region contains 2 SNPs
(rs425328 and rs1912826) that lie in the intergenic space between the genes KLKB1, FXI, and CYP4V2. E) Region plot
investigation identifies SNP rs4253238 as the main associated SNP in this region, with supporting evidence. F–H) Analysis of the
relationship bewween rs4253238 and serum scuPAR in the COPD cohort (n219; H) reveals that the same direction of effect
exists across the control (F) and asthma (G) populations. These differences were statistically significant (P0.001). Red lines
denote median scuPAR levels. *P  0.05, **P  0.001, ***P  0.0001.
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KLKB1 cleaves recombinant scuPAR in a cell-free
system
KLKB1 induces loss of the uPAR DI epitope, as evi-
denced by Western blotting using a DI-specific uPAR
monoclonal antibody (IIIF10) on recombinant uPAR
(ruPAR) incubated with KLKB1 (Fig. 5F). No other
fragments were observed. Western blot analysis using
the uPAR polyclonal antibody BAF807 identified the
KLKB1-dependant loss of full-length ruPAR and pro-
duction of a 30-kDa fragment (Fig. 5G). N-terminal
sequencing identified the location of this fragment’s
N-terminal as adjacent to uPAR DIII (sequence THEP).
KLKB1-mediated uPAR cleavage was blocked through
the use of a protease inhibitor (Fig. 5F, G). Incubation
of recombinant uPAR with KLKB1 also rendered uPAR
undetectable by ELISA (see Supplemental Fig. S2).
KLKB1 reverses scuPAR-mediated effects on
bronchial epithelial cell proliferation and wound
repair
The effect of scuPAR on epithelial cell migration and
proliferation in relation to muPAR-driven effects was
investigated in HBECs recombinantly expressing an
engineered form of scuPAR (lacking GPI) or full-
length muPAR. Overexpression of scuPAR or muPAR
resulted in excess scuPAR in the cell supernatant and
attenuation of HBEC wound repair in a scratch-wound
model (P0.001; Fig. 6A) while scuPAR alone in-
creased cell proliferation (P2104; Fig. 6B). All
scuPAR-mediated effects were negated in the presence
of KLKB1 (Fig. 6A, B).
DISCUSSION
In the current study we aimed to investigate the expres-
sion profile of scuPAR in asthma and COPD and use
genetics to identify novel regulatory mechanisms. In
the initial part of this study we provide the first evi-
dence that serum-circulating scuPAR is elevated in
asthma and COPD. This identifies these populations as
suitable cohorts for genome-wide analyses carried out
to identify novel regulatory mechanisms in disease.
Using a genome-wide protein QTL mapping approach
we then identify a novel regulatory mechanism of
scuPAR expression, where scuPAR serum levels are
inversely correlated with serum KLKB1 activity, which is
driven by SNP rs4253238. Finally we identified that
KLKB1 modulation of scuPAR has implications for
scuPAR-driven effects on cell function, including both
proliferation and migration.
Our data suggest that serum scuPAR is associated
with asthma and COPD, with higher overall levels of
scuPAR detected in COPD, a highly neutrophilic dis-
ease characterized by less airway hyperresponsiveness
and reversibility when compared to asthma (39). This
Figure 3. SNP rs4253238 is in LD with other KLKB1 SNPs.
A) LD plot of the GWAS identified SNP rs4253238 identi-
fies a block of LD between this SNP and other SNPs present
in the KLKB1 gene, in the control/asthma data set
(n584). B) LD plot generated with Haploview, utilizing
HapMap data selected for the CEU (Utah residents with
northern and western European ancestry) population,
confirms the presence of a block of LD for SNP rs4253238
with SNPs in the 5= region of the KLKB1 gene. Numbers
identify the R2 values up to a maximum of 100. The color
scheme denotes the level of LD as defined by D=. Similar
plots identify no LD with regions downstream of rs4253238
(data not shown).
Figure 4. KLKB1 does not alter PLAUR mRNA expression.
Addition of KLKB1 to a population of primary HBECs did not
alter the rate of total PLAUR mRNA expression either at 4 or
24 h postexposure. This suggests that changes in circulating
levels of scuPAR driven by KLKB1 are not driven by changes
in mRNA expression patterns.
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extends our previous work, where we identified an
elevated level of uPAR in the airway epithelium in
asthma (8), and suggests a systematic increase in this
integral protein.
scuPAR is thought to be generated from membrane
uPAR by the activity of a number of different enzymes,
including phospholipases C and D, which cleave the
receptor’s GPI anchor (5, 40). Similarly, a number of
different proteases, including pepsin, MMP-12, chymo-
trypsin, human airway trypsin-like protease, cathepsin
G, and urokinase, can cleave the receptor linker region
between DI and DII, (residues 83 to 89) to generate DI-
and DII/III-containing proteins (41–45). However, at
this time, the relevance of these or any other cleavage
mechanism ultimately determining serum levels of scu-
PAR (and other enzymatically generated forms) re-
mains to be clarified. To define novel regulatory mech-
anisms for scuPAR we utilized a protein QTL-mapping
approach. This decision was carried out based on
previous knowledge that protein QTL mapping can be
successfully employed to identify interactive protein
networks in humans and discover novel biological
mechanisms (46).
We identified rs4253238 as a promoter polymor-
phism with KLKB1, a chromosome 4q34-35 gene en-
coding prekallikrein (47). Prekallikrein, cleaved by
activated factor XII, with high-molecular-weight kinino-
gen as a cofactor, forms human plasma kallikrein
(KLKB1; ref. 47). Interestingly, an SNP (rs2731672) in
proximity (5897 bp) to the factor XII gene, nearly
achieved genome-wide significance in this study, sug-
gesting multiple functional SNPs in this pathway.
KLKB1 is a serine protease that circulates at a serum
concentration of 50 	g/ml (48) and participates in the
contact activation system of coagulation (49, 50) and
plasmin activation (51). Presence of the C allele of
rs4253238 results in the loss of 3 putative transcription
factor binding domains: neurogenic differentiation 1
(NeuroD1), Kruppel-like C2H2 zinc finger, and PAR/
pZIP family, suggesting a role for this SNP in KLKB1
regulation. High LD existed between rs4253238 and
other KLKB1 SNPs, but not any of the genes adjacent to
KLKB1. However, haplotype analysis identified that
rs4253238 may be simply a marker for an alternate
regulatory SNP. This hypothesis was further validated
by an in silico analysis of the potential functional effects,
where a number of SNPs in LD were shown to have
gene expression regulatory potential. A link between
rs4253238 and KLKB1 activity was confirmed through a
serum KLKB1 protease activity assay, with the C allele
associated with lower KLKB1 activity, forming an in-
verse KLKB1 activity/uPAR relationship. We confirmed
this relationship in the supernatant and total intracel-
lular protein of primary bronchial epithelial cells (a
major source of uPAR in the airways). Although the
relationship between KLKB1 and uPAR levels was not
unique to diseased populations, we identified overall
reduced KLKB1 activity in the asthma and COPD
Figure 5. SNP rs4253238 modulates KLKB1 enzymatic
activity, which, in turn, determines scuPAR levels. A)
KLKB1 activity assay identified an elevation of KLKB1
activity with the rs4253238 T:T genotype in control (P0.004), asthma (P0.034), and COPD (P0.011) populations.
KLKB1 activity was also found to be reduced in the 2 diseased populations when compared to controls (P1104). B)
KLKB1 activity was found to be inversely correlated with scuPAR levels regardless of whether the subjects were controls,
patients with asthma, or patients with COPD (P1104; R20.278). C, D) Exposure of NHBECs to plasma-extracted
human KLKB1 results in reduced levels of scuPAR in cell supernatants at 4 and 24 h (P0.015 and P0.029, respectively;
C), while total intracellular protein was decreased at 24 h (P0.05; D). E) Within the same cell system, plasmin was activated
by KLKB1 at 4 h, but not at 24 h (P5103), identifying the need for a cell-free system to investigate the direct effect of
KLKB1 on scuPAR. F, G) Staining of recombinant human uPAR (ruPAR) digested with KLKB1 with the uPAR DI-specific
monoclonal antibody IIIF10 (F) and the polyclonal antibody BAF 807 (G) reveals that KLKB1 proteolytically cleaves the
ruPAR molecule at the DI region (F), leaving behind a fragment of 30 kDa, comparable to that formed following
digestion of a known uPAR proteolytic enzyme, chymotrypsin (P0.001). I, ruPAR; II, ruPAR 
 KLKB1; III, ruPAR 

chymotrypsin; IV, ruPAR 
 KLKB1 
 protease inhibitor cocktail. *P  0.05, **P  0.001.
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populations, which may at least in part contribute to
the elevated scuPAR levels detected in these disease
populations. Therefore, although KLKB1 regulation of
scuPAR is a regulatory pathway observed in both dis-
ease and control populations, results from the activity
assay and GWAS heterogeneity tests allow us to propose
a significantly reduced KLKB1 activity in obstructive
lung disease. This would significantly contribute to the
elevated levels of scuPAR in serum detected in this
study and in multiple other diseases in previous inves-
tigations (22).
To further define the mechanism driving KLKB1
regulation of scuPAR levels and to remove any possible
confounding effect by the uPAR GPI anchor protease
plasmin, which has been shown to be elevated by
KLKB1 (51), we carried out experiments using a cell-
free system. Incubation of recombinant uPAR with
KLKB1 resulted in loss of DI, while N-terminal sequenc-
ing identified a cleavage site adjacent to DIII. Regula-
tion of scuPAR by KLKB1 via a direct proteolytic
mechanism correlates well with a previous investigation
into relationships between human tissue kallikrein
(hK4), a nonhomologous relative of KLKB1, and uPAR
(52). Recently reported proteolytic effects of KLKB1 on
other molecules such as endothelin-1 and adrenomedullin
(53) also lend weight to this argument. We therefore
conclude that KLKB1 regulates uPAR levels by acting as
an uPAR proteolytic enzyme, in a plasmin-independent
manner.
Disease and biological roles for uPAR have already
been described at the cellular level. Increased uPAR
expression has been determined at the leading edge of
reepithelializing wounds (8), while uPAR-dependent
activation of TGF and hepatocyte growth factor/
scatter factor (HGF/SF) is known to increase the rate of
proliferation in epithelial cells (54). We therefore set
out to determine whether the soluble cleaved form of
the receptor has its own independent role on epithelial
function and whether KLKB1 is capable of inhibiting
these effects.
Soluble cleaved uPAR has been shown to be biolog-
ically active in epithelial cells (8). In this study we have
extended this observation, identifying a physiological
role for scuPAR in HBECs, where scuPAR modulates
proliferation and wound repair. Soluble cleaved uPAR
attenuates the rate of wound repair to a similar degree
as muPAR (8) and independently increases the rate of
proliferation, with addition of KLKB1 successfully in-
hibiting these effects. This is in good agreement with
previously published work on the effect of KLKB1, on
epithelial wound repair (55). Here Lund et al. (55)
describe how inhibition of KLKB1 activity leads to
strong attenuation of wound repair in a mouse model
independently of both uPA and tPA. Although unre-
ported by the authors, it is likely that the reported
effect may be due to attenuated cleavage of uPAR. As
both attenuated wound repair and increased prolifera-
tion are important contributing factors toward airway
remodeling (56, 57), it is likely that modulation of
these cell mechanisms by scuPAR and KLKB1 may
contribute to disease where epithelial function plays a
crucial role, such as obstructive lung disease, FSGS, and
certain cancers.
It is likely that the rs4253238 SNP may also be of
relevance to other KLKB1-driven disease processes
through its modulation of KLKB1 activity. KLKB1 has a
known proteolytic function, activating a number of
proteins including bradykinin and blood clotting factor
XII (58). Interestingly, a FXII SNP demonstrated near
genome-wide significance with serum scuPAR levels in
the current study and FXII has been shown to interact
with uPAR to stimulate ERK1/2 and Akt signaling
pathways (59). KLKB1 has also been implicated in the
stimulation of neutrophil chemotaxis, aggregation, and
Figure 6. scuPAR-driven alterations in HBEC functions are attenuated by KLKB1. A)
scuPAR attenuates wound repair in a scratch-wound model when compared to the
empty vector control at the 4 h (P0.001) and 8 h (P0.05) time points, an effect
mirrored by muPAR (P0.01). B) scuPAR also increases bronchial epithelial cell
proliferation (P2104), while muPAR does not alter the rate of proliferation. C,
D) Addition of KLKB1 negates all scuPAR-driven effects. Overexpression of scuPAR
and muPAR by the transiently transfected primary HBECs was confirmed both in cell
supernatant by ELISA (P2.6103; C) and in cell lysate by Western blotting
(P1.3103; D), where KLKB1 was found to reduce scuPAR overexpression
(P0.001). *P  0.05, **P  0.001, ***P  0.0001.
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oxygen consumption (60). The majority of known
KLKB1 activity is attributed to the cleavage of these 2
substrates/cofactors and regulation of neutrophil func-
tion, including effects on inflammation, vascular func-
tion, blood pressure regulation, and nociceptive re-
sponses (61). This could be of relevance to multiple
diseases including lung disease, where both neutro-
philic inflammation, e.g., severe asthma and COPD,
and the fibrinolytic/coagulation cascade, e.g., asthma,
COPD and idiopathic pulmonary fibrosis, have been
implicated.
In summary, we identified elevated circulating serum
scuPAR in asthma and COPD. We completed a human
genome-wide protein QTL map, identifying a post-
translational serum scuPAR regulatory mechanism
through an association with KLKB1 promoter SNP
rs4253238. The rs4253238-associated protein KLKB1
regulates scuPAR levels through KLKB1-mediated pro-
teolytic cleavage at the protein’s DI region. This pro-
teolytic mechanism in turn modulates alteration in
epithelial wound repair and proliferation (Fig. 6).
Cleavage also results in scuPAR being unable to interact
with integrins (62, 63) or sequester circulating uroki-
nase (2), effecting the modulation of uPAR associated
diseases (Fig. 7). Although common to both the dis-
eased and nondiseased populations, we identify differ-
ences in activity between diseased (COPD/asthma) and
control populations. SNP rs4253238 is also a prevalent
SNP (MAF0.496; HapMap CEU population) making
it a potential widespread regulator of scuPAR with
relevance in multiple human conditions, although fur-
ther studies are needed to identify the SNPs in the
rs4253238 LD block that are functionally relevant. We
therefore hypothesize that KLKB1-mediated reduction
of scuPAR as identified in this study may play an
important role in scuPAR-associated diseases, such as
prostate (10) and breast (9) cancers, epilepsy (11),
cardiovascular disease (12), and FSGS (24).
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